Difference between revisions of "Sunitinib (Sutent)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
Line 11: | Line 11: | ||
*[[Renal cancer]] | *[[Renal cancer]] | ||
*[[Sarcoma]] | *[[Sarcoma]] | ||
+ | *[[Small cell lung cancer]] | ||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
*[[Thymoma]] | *[[Thymoma]] | ||
Line 27: | Line 28: | ||
==Also known as== | ==Also known as== | ||
− | SU11248, SU011248 | + | *'''Code names:''' SU11248, SU011248 |
+ | *'''Brand name:''' Sutent | ||
==References== | ==References== | ||
Line 33: | Line 35: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
− | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Line 47: | Line 48: | ||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
[[Category:Sarcoma medications]] | [[Category:Sarcoma medications]] | ||
+ | [[Category:Small cell lung cancer medications]] | ||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] |
Revision as of 18:00, 24 August 2017
General information
Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including: vascular endothelial growth factor receptor (VEGFR1, VEGFR2 and VEGFR3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and RET. Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Hepatobiliary cancer
- Pancreatic neuroendocrine islet cell tumors
- Renal cancer
- Sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Thyroid cancer
Patient drug information
- Sunitinib (Sutent) package insert[1]
- Sunitinib (Sutent) patient drug information (Chemocare)[4]
- Sunitinib (Sutent) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1/26/2006: Initial FDA approval:
- "for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate."
- "for the treatment of advanced renal cell carcinoma."
- 5/20/2011: FDA approved for treatment of "Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease."
Also known as
- Code names: SU11248, SU011248
- Brand name: Sutent
References
- Drug index
- Oral medications
- Kinase inhibitors
- FLT3 inhibitors
- KIT inhibitors
- PDGFR inhibitors
- RET inhibitors
- VEGF inhibitors
- Hepatobiliary cancer medications
- Neuroendocrine tumor medications
- Renal cancer medications
- Sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Thyroid cancer medications
- Drugs FDA approved in 2006